Abstract
A study was started in 1976 whereby patients with Stage II and operable Stage III MBC were given adjuvant Tamoxifen for 1 year, increasing to 2 years from 1988. All patients had axillary nodal involvement. Primary treatment consisted of a radical mastectomy or simple mastectomy with radiotherapy. The rarity of the disease precluded a randomised trial. Thirty-nine patients are available for analysis at a median follow-up of 49 months. The actuarial survival of the Tamoxifen treated patients is 61% (range 42-80%) at 5 years compared to 44% (range 35-53%) for historical controls (P = 0.006). Disease-free survival was 56% (37-75%) vs 28% (17-33%) at 5 years (P = 0.005). There were no serious side-effects recorded. The conclusion from this, the first reported series on adjuvant Tamoxifen therapy for MBC, is that significant improvement in disease-free survival can be achieved with minimal upset to the patients. Recruitment to the study continues.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ribeiro, G., Swindell, R. Adjuvant Tamoxifen for male breast cancer (MBC). Br J Cancer 65, 252–254 (1992). https://doi.org/10.1038/bjc.1992.50
Issue Date:
DOI: https://doi.org/10.1038/bjc.1992.50
This article is cited by
-
Survival benefit of tamoxifen in male breast cancer: prospective cohort analysis
British Journal of Cancer (2020)
-
Intracystic papillary carcinoma of the male breast: a case report
World Journal of Surgical Oncology (2018)
-
Survival Comparisons Between Early Male and Female Breast Cancer Patients
Scientific Reports (2018)
-
Survival benefit of tamoxifen and aromatase inhibitor in male and female breast cancer
Journal of Cancer Research and Clinical Oncology (2018)
-
Cancer du sein chez l’homme : ce qui différencie les hommes des femmes
Psycho-Oncologie (2017)